IDH1 R132

P3, N=245, Recruiting, Servier Affaires Médicales | Trial completion date: Dec 2026 --> Oct 2027 | Trial primary completion date: Jan 2026 --> Oct 2027

A prospective IDH1 R132C clinical-matrix spike-in further supported sub-1% detection without pre-amplification. Collectively, this work establishes a configurable Cas13d toolkit and a rule-guided strategy for deploying CRISPR-based RNA SNV diagnostics with application-specific performance objectives.

This study demonstrates that increased expression of autophagy-related genes, particularly SQSTM1 and Beclin1, serves as a robust indicator of poor prognosis and shorter survival times in diffuse astrocytic tumors. Furthermore, the elevated expression of Beclin1 and Atg5 in IDH-mutant cases highlights a complex metabolic interplay that warrants further investigation as potential therapeutic targets.

To the best of our knowledge, this is the first reported case of cytology of DDCS in effusion cytology. This case highlights the exceptional metastatic potential of DDCS and underscores the critical role of cytology, supported by clinicoradiologic and immunocytochemical correlation, in diagnosing rare metastatic presentations in serous effusions.

P3, N=245, Recruiting, Servier Affaires Médicales | N=179 --> 245

Clinical validation has confirmed that this dual-channel synergistic detection strategy can accurately identify the IDH1.R132H mutation in glioma patients with as little as 1 µL of sample, and deliver crucial clinical information such as tumor size and staging. This label-free, rapid, cost-effective, and highly sensitive biosensing platform offers a powerful tool for early cancer screening, molecular diagnostics, and longitudinal disease monitoring.

The patient received adjuvant radiotherapy (40 Gy/15 fractions) and is under 5-year letrozole therapy...This case underscores the clinical, histopathological, immunophenotypic, and molecular features of TCCRP, including the rare IDH1 R132H mutation. Timely surgical and hormonal therapy ensures excellent prognosis, and future studies on targeted IDH1/IDH2 and PIK3CA therapies may expand treatment options.

P3, N=560, Recruiting, CarThera | Active, not recruiting --> Recruiting

Real-world data from our cohort and the TriNetX database support the oncological outcomes reported in the ClarIDHy trial and other real-world cohorts.

In this hospital-based cross-sectional study, IDH1 (R132H) IHC-negative status was more frequently observed in higher-grade tumors. These findings support the use of immunohistochemistry as an accessible adjunct in glioma diagnosis and clinicopathological stratification; outcome-based prognostic significance requires longitudinal follow-up.

Notably, the oncogenic idh1*R132H variant also rescued the pronephric defects induced by idh1 knockdown, indicating that its neomorphic activity is absent under embryonic metabolic conditions. These findings identify Idh1 and Idh2 as key regulators of pronephric morphogenesis and reveal a developmental function of Idh1 that is distinct from its canonical catalytic role.

P1, N=166, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2027 --> Oct 2030